Kathleen Tregoning - 09 Feb 2022 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc.

Role
Chief Corporate Affairs Officer
Signature
/s/ Mark Bodenrader, as Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
09 Feb 2022
Net transactions value
$0
Form type
4
Filing time
11 Feb 2022, 17:39:53 UTC
Previous filing
07 Jan 2022
Next filing
19 Sep 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CERE Stock Option (Right to Buy) Award $0 +63,321 $0.000000 63,321 09 Feb 2022 Common Stock 63,321 $30.36 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of this option shall vest and become exercisable on February 9, 2023, with the remainder vesting in thirty-six (36) monthly installments thereafter.

Remarks:

Chief Corporate Affairs Officer